Amicus Therapeutics, Inc. Information Request Form

Levi & Korsinsky, LLP has commenced an investigation into the fairness of the merger of Amicus Therapeutics, Inc. (NASDAQ: FOLD) (“Amicus” or the “Company”) with ARYA Sciences Acquisition Corp IV. Upon the closing of the transaction, Amicus will become the largest shareholder in Caritas with a ~36% ownership stake (assuming no redemptions by ARYA’s shareholders) and retain co-development and commercialization rights to the Fabry and Pompe gene therapy programs as well as negotiation rights on select future muscular dystrophy programs.

The Amicus merger investigation concerns whether the Board of Amicus has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.